Related references
Note: Only part of the references are listed.TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status
Chen Liang et al.
AUTOPHAGY (2020)
The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer
Si Shi et al.
ANNALS OF SURGERY (2020)
Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis
Andrea Lisotti et al.
GASTROINTESTINAL ENDOSCOPY (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Inhibition of TGF-beta signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models
Eunji Hong et al.
SCIENTIFIC REPORTS (2020)
ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
Neha Nanda et al.
GENES (2020)
Human organoids: model systems for human biology and medicine
Jihoon Kim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
V. Chung et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis
Sally Temraz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
Epidemiology and burden of pancreatic cancer
Patrick Maisonneuve
PRESSE MEDICALE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
E. M. O'Reilly et al.
ANNALS OF ONCOLOGY (2019)
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Kyle C. Cuneo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Samantha A. Armstrong et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Mutant p53 as a guardian of the cancer cell
Fiamma Mantovani et al.
CELL DEATH AND DIFFERENTIATION (2019)
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
Vincent Bernard et al.
GASTROENTEROLOGY (2019)
Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features
Yuko Omori et al.
GASTROENTEROLOGY (2019)
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
Fumiaki Watanabe et al.
PLOS ONE (2019)
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains
Dongju Park et al.
PLOS ONE (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Identification of targetable BRAFΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
Kazimierz O. Wrzeszczynski et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer
Sofia Palacio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Angela Chou et al.
GUT (2018)
Efforts to Develop KRAS Inhibitors
Matthew Holderfield
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
KRAS mutations in cell- free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study
Yutaka Nakano et al.
BRITISH JOURNAL OF CANCER (2018)
SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy
Feng Wang et al.
CLINICAL CANCER RESEARCH (2018)
The role of TGF-beta/SMAD4 signaling in cancer
Ming Zhao et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Eric Van Cutsem et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Chunling Hu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Emerging strategies in BRCA-positive pancreatic cancer
Adam Kowalewski et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Ruth Perets et al.
ONCOLOGIST (2018)
Challenges in diagnosis of pancreatic cancer
Lulu Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Clare Fiala et al.
BMC MEDICINE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic testing for pancreatic cancer in clinical practice as real-world evidence
Hideyuki Hayashi et al.
PANCREATOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Vasilios Karavasilis et al.
TARGETED ONCOLOGY (2018)
Targeting mutant p53 in cancer: a long road to precision therapy
Fiamma Mantovani et al.
FEBS JOURNAL (2017)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem et al.
TARGETED ONCOLOGY (2017)
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
Thales C. Nepomuceno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
Chen Liang et al.
MOLECULAR CANCER RESEARCH (2017)
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Prasenjit Dey et al.
NATURE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells
Daichi Kawamura et al.
ONCOLOGY REPORTS (2017)
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Joshua D. Cohen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy SWOG S1115 Study Randomized Clinical Trial
Vincent Chung et al.
JAMA ONCOLOGY (2017)
Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer
Sujuan Yang et al.
CANCER BIOLOGY & THERAPY (2017)
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2017)
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage
Lukas Perkhofer et al.
CANCER RESEARCH (2017)
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX
Carole Vitellius et al.
CLINICAL DRUG INVESTIGATION (2017)
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
Talia Golan et al.
BRITISH JOURNAL OF CANCER (2017)
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
K. Allenson et al.
ANNALS OF ONCOLOGY (2017)
Inhibitors of Ras-SOS Interactions
Shaoyong Lu et al.
CHEMMEDCHEM (2016)
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
Kjersti Tjensvoll et al.
MOLECULAR ONCOLOGY (2016)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015)
B. H. O'Neil et al.
ANNALS OF ONCOLOGY (2016)
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster et al.
CANCER CELL (2016)
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
D. J. Renouf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation (vol 165, pg 910, 2016)
Christopher J. Tape et al.
CELL (2016)
TGF-β Tumor Suppression through a Lethal EMT
Charles J. David et al.
CELL (2016)
FBW7 (F-box andWDRepeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Shunrong Ji et al.
CLINICAL CANCER RESEARCH (2016)
Islet biology, the CDKN2A/B locus and type 2 diabetes risk
Yahui Kong et al.
DIABETOLOGIA (2016)
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Barbara Bournet et al.
EUROPEAN JOURNAL OF CANCER (2016)
Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib
Ganji Purnachandra Nagaraju et al.
EUROPEAN JOURNAL OF CANCER (2016)
Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma
Christopher C. DuFort et al.
GASTROENTEROLOGY (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
Anne M. Noonan et al.
MOLECULAR THERAPY (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment
Jana K. Striefler et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
KRAS-related proteins in pancreatic cancer
Karen M. Mann et al.
PHARMACOLOGY & THERAPEUTICS (2016)
p53 and p16Ink4a/p19Arf Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells
Stephanie Azzopardi et al.
NEOPLASIA (2016)
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Daniel Zeitouni et al.
CANCERS (2016)
Modeling Pancreatic Cancer with Organoids
Lindsey A. Baker et al.
TRENDS IN CANCER (2016)
Pancreatic cancer biology and genetics from an evolutionary perspective
Alvin Makohon-Moore et al.
NATURE REVIEWS CANCER (2016)
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
Rory J. Makielski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
S. Kordes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma
Martin C. Whittle et al.
CELL (2015)
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Sylvia F. Boj et al.
CELL (2015)
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
Shunrong Ji et al.
CELL RESEARCH (2015)
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
A. H. Ko et al.
CLINICAL CANCER RESEARCH (2015)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill et al.
CLINICAL CANCER RESEARCH (2015)
BRAF inhibitors: the current and the future
Weijiang Zhang
CURRENT OPINION IN PHARMACOLOGY (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
Jon J. G. Winter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
Jeong Won Lee et al.
MEDICINE (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Ataxia-telangiectasia-Mutated Protein Kinase Levels Stratify Patients With Pancreatic Adenocarcinoma Into Prognostic Subgroups With Loss Being a Strong Indicator of Poor Survival
Carsten Kamphues et al.
PANCREAS (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Targeting Oncogenic Mutant p53 for Cancer Therapy
Alejandro Parrales et al.
FRONTIERS IN ONCOLOGY (2015)
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
David B. Zhen et al.
GENETICS IN MEDICINE (2015)
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
D. Propper et al.
ANNALS OF ONCOLOGY (2014)
Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer
Jing Xu et al.
BMC CANCER (2014)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
Haeryoung Kim et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
Patricia Izetti et al.
INVESTIGATIONAL NEW DRUGS (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma
Bruno V. Sinn et al.
PANCREAS (2014)
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
J. Xu et al.
CELL DEATH & DISEASE (2014)
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
Dana B. Cardin et al.
CANCER MEDICINE (2014)
Activated Ras signaling pathways and reovirus oncolysis an update on the mechanism of preferential reovirus replication in cancer cells
Jun Gong et al.
FRONTIERS IN ONCOLOGY (2014)
Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
Minoru Oshima et al.
ANNALS OF SURGERY (2013)
Failure Patterns in Resected Pancreas Adenocarcinoma Lack of Predicted Benefit to SMAD4 Expression
Jordan M. Winter et al.
ANNALS OF SURGERY (2013)
Roles for KRAS in Pancreatic Tumor Development and Progression
Marina Pasca di Magliano et al.
GASTROENTEROLOGY (2013)
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
Volker Heinemann et al.
GUT (2013)
Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics
Shiv K. Singh et al.
GUT (2013)
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
Sil Kordes et al.
INVESTIGATIONAL NEW DRUGS (2013)
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
Hong-Quan Duong et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes
Jalal Taneera et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Cosimo Commisso et al.
NATURE (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival
Sang Hyun Shin et al.
PANCREAS (2013)
The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma
Yanli Luo et al.
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tumour-associated mutant p53 drives the Warburg effect
Cen Zhang et al.
NATURE COMMUNICATIONS (2013)
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
J. B. Bachet et al.
ANNALS OF ONCOLOGY (2012)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
Femme Harinck et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2012)
Regulation of EMT by TGFβ in cancer
Carl-Henrik Heldin et al.
FEBS LETTERS (2012)
What We Have Learned About Pancreatic Cancer From Mouse Models
Pedro A. Perez-Mancera et al.
GASTROENTEROLOGY (2012)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
A. B. El-Khoueiry et al.
INVESTIGATIONAL NEW DRUGS (2012)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Meredith A. Collins et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
Puneet Singh et al.
PANCREAS (2012)
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
Meredith A. Collins et al.
PLOS ONE (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Nicholas J. Roberts et al.
CANCER DISCOVERY (2012)
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Eric A. Collisson et al.
CANCER DISCOVERY (2012)
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
R. A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Synne Weden et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
Seung Tae Kim et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors
C. Romagosa et al.
ONCOGENE (2011)
EUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer
Asif Khalid et al.
PANCREATOLOGY (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
The ARF tumor suppressor: structure, functions and status in cancer
Peggy Ozenne et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
MECHANISMS OF DISEASE Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
Alan D. D'Andrea
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genomic Instability at Both the Base Pair Level and the Chromosomal Level Is Detectable in Earliest PanIN Lesions in Tissues of Chronic Pancreatitis
Mario Baumgart et al.
PANCREAS (2010)
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Jennifer P. Morton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation
Jinyun Chen et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
FAM/USP9x, a Deubiquitinating Enzyme Essential for TGFβ Signaling, Controls Smad4 Monoubiquitination
Sirio Dupont et al.
CELL (2009)
The Secret Life of Smad4
Jeffrey L. Wrana
CELL (2009)
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Amanda Blackford et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification and Characterization of a Novel Anticancer Agent With Selectivity Against Deleted in Pancreatic Cancer Locus 4 (DPC4)-Deficient Pancreatic and Colon Cancer Cells
Hong Wang et al.
PANCREAS (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
p53-a Jack of all trades but master of none
Melissa R. Junttila et al.
NATURE REVIEWS CANCER (2009)
The expanding universe of p53 targets
Daniel Menendez et al.
NATURE REVIEWS CANCER (2009)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
Volker Heinemann et al.
BMC CANCER (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
Nabeel Bardeesy et al.
GENES & DEVELOPMENT (2006)
The regulation of INK4/ARF in cancer and aging
William Y. Kim et al.
CELL (2006)
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells
Hong Wang et al.
CANCER RESEARCH (2006)
p16INK4a induces an age-dependent decline in islet regenerative potential
Janakiraman Krishnamurthy et al.
NATURE (2006)
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing
Anna V. Molofsky et al.
NATURE (2006)
Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
N Bardeesy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Molecular mechanisms of pancreatic carcinogenesis
T Furukawa et al.
CANCER SCIENCE (2006)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Germ-layer specification and control of cell growth by ectodermin, a Smad4 ubiquitin ligase
S Dupont et al.
CELL (2005)
Precursors to invasive pancreatic cancer
A Maitra et al.
ADVANCES IN ANATOMIC PATHOLOGY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
INK4/ARF germline alterations in pancreatic cancer patients
P Ghiorzo et al.
ANNALS OF ONCOLOGY (2004)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms
MG House et al.
ANNALS OF SURGERY (2003)
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma
AV Biankin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Aberrant methylation of preproenkephalin and p16 genes in pancreatic Intraepithelial neoplasia and pancreatic ductal adenocarcinoma
N Fukushima et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine
CM Galmarini et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas - A new marker of DPC4 inactivation
RE Wilentz et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
